This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Bio-Rad
other brands :
Biogenesis, Serotec, AbD Serotec, Oxford Biotechnology
product type :
antibody
product name :
STUB1 antibody
catalog :
VMA00607KT
quantity :
2 Westerns
price :
108 USD
clonality :
monoclonal
host :
human
conjugate :
nonconjugated
reactivity :
human, rat
application :
western blot
product information
EntityType :
PrecisionAbâ„¢ Monoclonal
EntityCategory :
Antibodies
ProductCode :
VMA00607KT
Description :
STUB1 ANTIBODY WITH CONTROL LYSATE
Specificity :
STUB1
TargetSpecies :
Human
Host :
Human
Format :
Purified
Isotypes :
HuCAL Fab bivalent
Applications :
WB
ApplicationTypes :
Western Blotting
CrossReactivities :
Rat
Quantity :
2 Westerns
QuantityValue :
2
QuantityType :
Westerns
GOAccessions :
GO:0000151, GO:0000209, GO:0030674, GO:0005737, GO:0006515, GO:0051787, GO:0051879, GO:0019900, GO:0030544, GO:0030579, GO:0030911, GO:0031371, GO:0031398, GO:0031943, GO:0032436, GO:0034450, GO:0042405, GO:0042803, GO:0043161, GO:0046332, GO:0051604, GO:0051865, GO:0071218, GO:0090035
GOTerms :
activation of proteasomal ubiquitin-dependent protein catabolic process, activation of protein ubiquitination, degradation of misfolded or incompletely synthesized proteins, dimerization activity, E2 complex, E4, Hsp90 binding, Hsp90 class protein binding, misfolded or incompletely synthesized protein breakdown, misfolded or incompletely synthesized protein catabolism, misfolded or incompletely synthesized protein degradation, polyubiquitin, proteasomal pathway, proteasomal processing, proteasomal ubiquitin-dependent protein breakdown, proteasomal ubiquitin-dependent protein catabolism, proteasomal ubiquitin-dependent protein degradation, proteasome pathway, protein auto-ubiquitination, protein autoubiquitinylation, protein auto-ubiquitinylation, protein polyubiquitinylation, protein polyubiquitylation, protein self-ubiquitination, protein self-ubiquitinylation, protein-protein adaptor, regulation of glucocorticoid metabolism, stimulation of proteasomal ubiquitin-dependent protein catabolic process, stimulation of protein ubiquitination, ubiquitin-dependent SMAD protein breakdown, ubiquitin-dependent SMAD protein catabolism, ubiquitin-dependent SMAD protein degradation, up regulation of proteasomal ubiquitin-dependent protein catabolic process, up regulation of protein ubiquitination, up-regulation of proteasomal ubiquitin-dependent protein catabolic process, upregulation of proteasomal ubiquitin-dependent protein catabolic process, upregulation of protein ubiquitination, up-regulation of protein ubiquitination
UniprotAccessions :
Q9UNE7
Gene :
STUB1
GeneID URL :
www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=10273
EntityFormats :
Purified
UNSPSC :
12352203
ProductForm :
Purified IgG - liquid
PriceDKK :
804
PrimarySecondary :
Primary
PriceGBP :
83
PriceEUR :
108
PriceUSD :
108 USD
PriceCHF :
126
PriceSEK :
1077
PriceNOK :
1070
company information
Bio-Rad
Endeavour House, Langford Business Park
Langford Lane, Kidlington
OXON, OX5 1GE
antibody_sales_uk@bio-rad.com
https://www.bio-rad-antibodies.com
1 800 265 7376 (North America)
44 (0)1865 852 700 (Rest of World)
headquarters: UK
Bio-Rad is one of the world's leading antibody manufacturers, offering over 12,000 antibodies and related reagents for a focused range of research areas such as immunology, cancer, veterinary research and cell biology through its antibody experts formerly known as AbD Serotec.
The range includes apoptosis kits, autophagy reagents, CD markers, epitope tag antibodies, immunology antibodies, neuroscience antibodies, and veterinary reagents.
Bio-Rad has an ISO 9001 and ISO 13485 certified production facility in the United Kingdom as well as ISO 9001 certified facilities in Germany and the United States.
Our expertise extends to traditional and recombinant antibody generation and production services. Our custom generation service delivers antibodies in as little as 8 weeks with greater than 90% success. The in vitro technology enables selection of antibodies to challenging targets, long term consistent supply, and provision of the antibody sequence.
At Bio-Rad we are committed to your success when using our antibodies and we focus on providing the technology, products and all the supporting information you need to excel in your research.